Genta Incorporated  

(Public, OTCMKTS:GNTAQ)   Watch this stock  
Find more results for OTC:GETA
Aug 29 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range     -
52 week 0.00 - 0.00
Open     -
Vol / Avg. 0.00/2.84M
Mkt cap 595,973.00
P/E     -
Div/yield     -
EPS -0.20
Shares     -
Beta -12.63
Inst. own     -

Key stats and ratios

Q1 (Mar '12) 2011
Net profit margin 130850.00% -35783.50%
Operating margin -288700.00% -9584.54%
EBITD margin - -9488.66%
Return on average assets 220.22% -462.09%
Return on average equity - -
Employees 21 -
CDP Score - -


200 Connell Dr
United States - Map
+1-908-2869800 (Phone)
+1-302-6555049 (Fax)


Genta Incorporated (Genta) is a biopharmaceutical company engaged in pharmaceutical (drug) research and development. The Company is engaged in the identification, development and commercialization of novel drugs that is chiefly intended for the treatment of cancer and related diseases. The Company's lead compound is tesetaxel, a novel taxane compound that is taken by mouth. Tesetaxel has completed Phase II trials in a number of cancer types. Clinical trials conducted by the Company have confirmed that the drug has definite antitumor activity in gastric cancer and breast cancer. Tesetaxel appears to be associated with a substantially lower incidence of side effects, particularly hypersensitivity reactions and peripheral nerve damage, both of which are common side effects of taxanes. The Company's other pipeline project consists of the development of an orally bioavailable gallium-containing compound.